Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men

Clinical Endocrinology

Volumn 69, Issue 1, 2008, Pages 45-51

  Chan, Dick C ^a   Watts, Gerald F ^a   Wang, Jian ^b   Hegele, Robert A ^b   Van Bockxmeer, Frank M ^c   Barrett, P Hugh R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; CAMPESTEROL; GENE PRODUCT; ISOTOPE; LATHOSTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIEMAN PICK C1 LIKE 1 PROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALLELE; ARTICLE; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EVENING DOSAGE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; KINETICS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; MULTIPLE REGRESSION; OBESITY; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; WAIST CIRCUMFERENCE;

ADULT; ANTI-OBESITY AGENTS; APOLIPOPROTEIN B-100; CHOLESTEROL, VLDL; DRUG RESISTANCE; GENETIC VARIATION; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINETICS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OBESITY; PYRROLES; TREATMENT OUTCOME;

EID: 45349087988     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03144.x     Document Type: Article

References (24)

1. Despres, J.P., Moorjani, S., Lupien, P.J., Tremblay, A., Nadeau, A. Bouchard, C. (1990) Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis, Thrombosis and Vascular Biology, 10, 497 511.
2. Chan, D.C., Watts, G.F., Redgrave, T.G., Mori, T.A. Barrett, P.H. (2002) Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism, 51, 1041 1046.
3. Watts, G.F., Riches, F.M., Humphries, S.E., Talmud, P.J. van Bockxmeer, F.M. (2000) Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. Journal of Lipid Research, 41, 481 488.
4. Chan, D.C., Watts, G.F., Barrett, P.H.R., Whitfield, A.J. van Bockxmeer, F.M. (2004) ATP-binding cassette transporter G8 gene as a determinant of apolipoprotein B-100 kinetics in overweight men. Arteriosclerosis, Thrombosis and Vascular Biology, 24, 2188 2191.
5. Miettinen, T.A., Tilvis, R.S. Kesaniemi, Y.A. (1990) Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. American Journal of Epidemiology, 131, 20 31.
6. Simonen, P.P., Gylling, H. Miettinen, T.A. (2002) Body weight modulates cholesterol metabolism in non-insulin dependent type 2 diabetics. Obesity Research, 10, 328 335.
7. Chan, D.C., Watts, G.F., Barrett, P.H.R., O'Neill, F.H., Redgrave, T.G. Thompson, G.R. (2003) Relationship between cholesterol homeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clinical Science, 104, 383 388.
8. Hubacek, J.A., Berge, K.E., Cohen, J.C. Hobbs, H.H. (2001) Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Human Mutation, 18, 359 360.
9. Davies, J.P., Scott, C., Oishi, K., Liapis, A. Ioannou, Y.A. (2005) Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. Journal of Biological Chemistry, 280, 12710 12720.
10. Davies, J.P. Ioannou, Y.A. (2006) The role of the Niemann-Pick C1-like 1 protein in the subcellular transport of multiple lipids and their homeostasis. Current Opinion in Lipidology, 17, 221 226.
11. Iyer, S.P., Yao, X., Crona, J.H., Hoos, L.M., Tetzloff, G., Davis, H.R., Graziano, M.P. Altmann, S.W. (2005) Characterization of the putative native and recombinant rat sterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein. Biochimica et Biophysica Acta, 1722, 282 292.
12. Goldberg, R.B., Mellies, M.J., Sacks, F.M., Moye, L.A., Howard, B.V., Howard, W.J., Davis, B.R., Cole, T.G., Pfeffer, M.A. Braunwald, E. (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation, 98, 2513 2519.
13. Chan, D.C., Watts, G.F., Barrett, P.H., Mori, T.A., Beilin, L.J. Redgrave, T.G. (2002) Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. Journal of Clinical Endocrinology and Metabolism, 87, 2283 2289.
14. Chasman, D.I., Posada, D., Subrahmanyan, L., Cook, N.R., Stanton, V.P. Ridker, P.M. (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA, 291, 2821 2827.
15. Alberti, K.G.M.M., Zimmet, P. Shaw, J. IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome - a new worldwide definition. Lancet, 366, 1059 1062.
16. Egusa, G., Brady, D.W., Grundy, S.M. Howard, B.V. (1983) Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. Journal of Lipid Research, 24, 1261 1267.
17. Cummings, M.H., Watts, G.F., Lumb, P.J. Slavin, B.M. (1994) Comparison of immunoturbidimetric and Lowry methods for measuring concentration of very low density lipoprotein apolipoprotein B-100 in plasma. Journal of Clinical Pathology, 47, 176 178.
18. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412 419.
19. Hegele, R.A., Guy, J., Ban, M.R. Wang, J. (2005) NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids in Health and Disease, 4, 16.
20. Hixson, J.E. Vernier, D.T. (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. Journal of Lipid Research, 31, 545 548.
21. Cohen, J.C., Pertsemlidis, A., Fahmi, S., Esmail, S., Vega, G.L., Grundy, S.M. Hobbs, H.H. (2006) Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proceedings of the National Academy of Sciences of the USA, 103, 1810 1815.
22. Simon, J.S., Karnoub, M.C., Devlin, D.J., Arreaza, M.G., Qiu, P., Monks, S.A., Severino, M.E., Deutsch, P., Palmisano, J., Sachs, A.B., Bayne, M.L., Plump, A.S. Schadt, E.E. (2005) Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics, 86, 648 656.
23. Wang, J., Williams, C.M. Hegele, R.A. (2005) Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clinical Genetics, 67, 175 177.
24. Temel, R.E., Tang, W., Ma, Y., Rudel, L.L., Willingham, M.C., Ioannou, Y.A., Davies, J.P., Nilsson, L.M. Yu, L. (2007) Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. Journal of Clinical Investigation, 117, 1968 1978.